F. Cavalli , O. Klepp , J. Renard , M. Röhrt , P. Alberto , for the E.O.R.T.C. Early Clinical Trials Group
{"title":"A phase II study of oral VP-16-213 in non-seminomatous testicular cancer","authors":"F. Cavalli , O. Klepp , J. Renard , M. Röhrt , P. Alberto , for the E.O.R.T.C. Early Clinical Trials Group","doi":"10.1016/0014-2964(81)90043-8","DOIUrl":null,"url":null,"abstract":"<div><p>In a disease-oriented phase <em>II</em> study, thirty-three patients with advanced non-seminomatous testicular cancer were treated with oral <em>VP-16-213 175 mg/m<sup>2</sup>/day</em> for three consecutive days repeated every week. All patients had previously received extensive chemotherapy and twenty patients also had prior radiotherapy, Of <em>30</em> evaluable patients, <em>6</em> experienced partial remission for a median duration of <em>3.5 months</em>, whereas minor regression or stabilization of the disease was achieved in <em>7</em> patients for a median duration of <em>2.5 months</em>. Leukopenia was dose-limiting and resulted in dose reduction or treatment delay in <em>55%</em> of the scheduled courses. The definite antitumor activity of <em>VP-16-213</em> in non-seminomatous testicular cancer warrants its incorporation into combination chemotherapy for this disease.</p></div>","PeriodicalId":100497,"journal":{"name":"European Journal of Cancer (1965)","volume":"17 2","pages":"Pages 245-249"},"PeriodicalIF":0.0000,"publicationDate":"1981-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0014-2964(81)90043-8","citationCount":"39","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cancer (1965)","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/0014296481900438","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 39
Abstract
In a disease-oriented phase II study, thirty-three patients with advanced non-seminomatous testicular cancer were treated with oral VP-16-213 175 mg/m2/day for three consecutive days repeated every week. All patients had previously received extensive chemotherapy and twenty patients also had prior radiotherapy, Of 30 evaluable patients, 6 experienced partial remission for a median duration of 3.5 months, whereas minor regression or stabilization of the disease was achieved in 7 patients for a median duration of 2.5 months. Leukopenia was dose-limiting and resulted in dose reduction or treatment delay in 55% of the scheduled courses. The definite antitumor activity of VP-16-213 in non-seminomatous testicular cancer warrants its incorporation into combination chemotherapy for this disease.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
